Physician profile
Tyson Runako Anderson
NPI 1619427390
$18,371.79
in general payments reported to CMS, 2019-2025
15 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.34 · 2022: $137 · 2023: $1,748 · 2024: $1,730 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,003 · Food and Beverage: $5,325 · Consulting Fee: $2,290 · Travel and Lodging: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,002.50 |
| Food and Beverage | $5,325.35 |
| Consulting Fee | $2,290.00 |
| Travel and Lodging | $1,598.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $15,662.97 | 2021-2025 | Yeztugo, Descovy, Biktarvy |
| Viiv Healthcare Company | $1,339.84 | 2022-2025 | Apretude, Cabenuva, Rukobia |
| Theratechnologies INC. | $485.74 | 2025 | Egrifta, Trogarzo |
| Abbvie INC. | $190.83 | 2025 | |
| Lundbeck LLC | $130.54 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.81 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $83.45 | 2022-2025 | Pifeltro |
| Otsuka America Pharmaceutical, INC. | $75.73 | 2025 | Rexulti |
| Novo Nordisk INC | $72.14 | 2025 | Wegovy |
| Pfizer INC. | $66.42 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.78 | 2025 | Trintellix |
| Lilly USA, LLC | $52.88 | 2025 | Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $21.38 | 2025 | Eliquis |
| Exact Sciences Corporation | $18.98 | 2025 | The Cologuard Plus Collection Kit |
| Tolmar, INC. | $14.30 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyson Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.